| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
L689560 targets the glycine co-agonist binding site on the GluN1 subunit of the NMDA receptor. The NMDA receptor is a ligand-gated ion channel that plays a key role in excitatory neurotransmission and synaptic plasticity. Glycine is a required co-agonist for NMDA receptor activation, and L689560 acts as a competitive antagonist at the glycine site, blocking receptor activation. By inhibiting NMDA receptor function, L689560 reduces excitotoxicity and has neuroprotective effects.
|
|---|---|
| ln Vitro |
L-689560 is an antagonist of 2-carboxytetrahydroquinoline [2].
In vitro, L689560 potently inhibits NMDA receptor activity by competitively antagonizing the glycine co-agonist site. The compound has been characterized in radioligand binding assays using [4'-³H]-L-689560 as a specific radioligand for the glycine site. L689560 inhibits NMDA receptor-mediated currents in electrophysiological studies, demonstrating its functional antagonism. The compound's high potency and selectivity for the glycine site make it a valuable tool for studying NMDA receptor pharmacology. |
| ln Vivo |
Following the suppression of glycine receptor and NMDA receptor (NMDAR) channel activity, L-689560 (1 mg/kg, ip) dramatically diminishes the neuroprotective effects of glycine. L-689560 prevents the MCAO model's glycine-induced rise in Akt phosphorylation [1].
In vivo, L689560 has been shown to have neuroprotective effects in animal models of cerebral ischemia. In a rat model of middle cerebral artery occlusion (MCAO), administration of L689560 at 1 mg/kg significantly reduced the neuroprotective effect of glycine, indicating that the compound antagonizes glycine-mediated neuroprotection. These findings suggest that L689560 may have potential in the research of stroke and other excitotoxic conditions. |
| Enzyme Assay |
The non-cellular assay for L689560 involves measuring its binding affinity for the glycine site on the NMDA receptor using radioligand binding assays. Membrane preparations from rat brain or cells expressing NMDA receptors are incubated with [4'-³H]-L-689560 or another glycine site radioligand (such as [³H]-MDL-105,519) in the presence of varying concentrations of unlabeled L689560. The inhibition of radioligand binding is measured, and the Ki is determined from competition curves.
|
| Cell Assay |
The cellular assay for L689560 involves treating neuronal cells or brain slices with the compound and measuring its effects on NMDA receptor-mediated currents using electrophysiological techniques. Whole-cell patch-clamp recordings are performed on cultured neurons or acute brain slices. NMDA receptor-mediated currents are evoked by application of NMDA and glycine, and the inhibition of these currents by L689560 is measured at various concentrations. The IC50 is determined from concentration-response curves.
|
| Animal Protocol |
Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) rat middle cerebral artery occlusion (MCAO) model [1]
Doses: 1 mg/kg given Medication: IP Experimental Results: Dramatically diminished the neuroprotective effect of glycine on glycine receptors. In the in vivo neuroprotection study, adult male Sprague-Dawley rats are subjected to middle cerebral artery occlusion (MCAO) to induce focal cerebral ischemia. L689560 is administered at a dose of 1 mg/kg, and the infarct volume is measured 24 hours after ischemia. The compound's ability to reduce infarct size and improve neurological outcomes is assessed. Glycine is co-administered in some studies to evaluate the antagonism of glycine-mediated neuroprotection. |
| ADME/Pharmacokinetics |
L689560 has a molecular weight of 380.23 and a molecular formula of C₁₇H₁₅Cl₂N₃O₃. The compound is soluble in DMSO. It should be stored in a dry, dark place at 0-4°C for short-term storage or at -20°C for long-term storage. The compound has a purity of >98%. L689560 should be handled with appropriate laboratory safety precautions.
|
| Toxicity/Toxicokinetics |
The toxicological profile of L689560 has not been extensively characterized in the published literature. As an NMDA receptor antagonist, it may have effects on learning, memory, and motor function at high doses. Comprehensive toxicology data are limited, and L689560 is not approved for clinical use. The compound should be handled with appropriate laboratory safety precautions.
|
| References |
|
| Additional Infomation |
(2R,4S)-4-[[aniline(oxo)methyl]amino]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid is a member of the quinoline class of compounds.
L689560 is a potent and selective glycine site NMDA receptor antagonist that has been used as a research tool to study NMDA receptor function and as a radioligand for the glycine site. Its high potency and selectivity make it a valuable tool for investigating the role of the glycine co-agonist site in NMDA receptor signaling and excitotoxicity. L689560 has been studied for its neuroprotective effects in models of cerebral ischemia. The compound is not approved for clinical use and is strictly a research tool. |
| Molecular Formula |
C17H15CL2N3O3
|
|---|---|
| Molecular Weight |
380.23
|
| Exact Mass |
379.049
|
| CAS # |
139051-78-8
|
| PubChem CID |
6604749
|
| Appearance |
White to off-white solid powder
|
| Density |
1.51g/cm3
|
| Boiling Point |
549.1ºC at 760 mmHg
|
| Melting Point |
172-173ºC
|
| Flash Point |
285.9ºC
|
| Vapour Pressure |
6.81E-13mmHg at 25°C
|
| Index of Refraction |
1.683
|
| LogP |
4.726
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
502
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1[C@@H](C2=C(C=C(C=C2Cl)Cl)N[C@H]1C(=O)O)NC(=O)NC3=CC=CC=C3
|
| InChi Key |
UCKHICKHGAOGAP-UONOGXRCSA-N
|
| InChi Code |
InChI=1S/C17H15Cl2N3O3/c18-9-6-11(19)15-12(7-9)21-14(16(23)24)8-13(15)22-17(25)20-10-4-2-1-3-5-10/h1-7,13-14,21H,8H2,(H,23,24)(H2,20,22,25)/t13-,14+/m0/s1
|
| Chemical Name |
(2R,4S)-5,7-dichloro-4-(phenylcarbamoylamino)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid
|
| Synonyms |
L-689560; L 689560; L689560
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6300 mL | 13.1499 mL | 26.2999 mL | |
| 5 mM | 0.5260 mL | 2.6300 mL | 5.2600 mL | |
| 10 mM | 0.2630 mL | 1.3150 mL | 2.6300 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
